Windsor Dermatology PC

1. Janssen Research & Development, LLC $667,578 70 payments
2. AbbVie, Inc. $625,925 101 payments
3. Takeda Pharmaceuticals U.S.A., Inc. $394,509 30 payments
4. LEO Pharma AS $353,678 56 payments
5. Boehringer Ingelheim Pharmaceuticals, Inc. $253,371 12 payments
6. Regeneron Pharmaceuticals, Inc. $185,769 456 payments
7. Sun Pharmaceutical Industries Inc. $147,475 21 payments
8. Incyte Corporation $50,639 24 payments
9. E.R. Squibb & Sons, L.L.C. $29,851 4 payments
10. Boehringer Ingelheim RCV GmbH & Co KG $54 1 payment

1. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period $394,509 30 payments
2. Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend $211,193 24 payments
3. Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis $199,119 21 payments
4. A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis $157,620 5 payments
5. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy $152,773 16 payments
6. BI 730357 PoCC and dose ranging in Psoriasis $130,845 3 payments
7. A Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp $105,942 11 payments
8. A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis $94,694 12 payments
9. A Prospective Observational Study of Adult Patients Receiving Dupixent for Atopic Dermatitis $93,236 209 payments
10. A Prospective Observational Study of Patients Receiving Dupixent for Atopic Dermatitis $92,533 247 payments

1. Professional salary support $105,942 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.